期刊
INTERNATIONAL JOURNAL OF ONCOLOGY
卷 34, 期 6, 页码 1505-1511出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo_00000279
关键词
RLIP76; PKC alpha; cancer; drug-resistance; glutathione-conjugate transport; doxorubicin
类别
资金
- NIH [CA 77495, CA 104661, ES 012171]
- Cancer Research Foundation of North Texas
- Institute for Cancer Research
- Joe and Jessie Crump Fund for Medical Education
- NATIONAL CANCER INSTITUTE [R01CA104661, R01CA077495] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012171] Funding Source: NIH RePORTER
Lung cancer is still a major cause of cancer deaths in spite of considerable efforts in its systemic therapy. Chemotherapy, along with local irradiation is frequently employed but as a palliative therapy. Inherent and acquired resistance in NSCLC and SCLC towards chemotherapeutic agents further makes chemotherapy an incommodious problem. The resistance mechanisms responsible for inherent DOX-resistance of NSCLC and acquired DOX-resistance in SCLC have been the subject of numerous investigations. This review will focus on the recent studies done for understanding the mechanism(s) of inherent and acquired resistance in NSCLC and SCLC and how these can be exploited for the future development of more effective novel biologic agents for the treatment of lung cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据